Publication Name	World Journal of Gastroenterology
Manuscript ID	18991
Country	United States

Received	2015-04-30 09:13
Peer-Review Started	2015-05-05 17:37
To Make the First Decision	2015-07-14 10:23
Return for Revision	2015-07-14 20:15
Revised	2015-07-27 13:07
Second Decision	2015-09-28 16:07
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2015-09-30 10:14
Articles in Press	2015-09-30 10:15
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-10-26 16:11
Publish the Manuscript Online	2015-11-11 13:34

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Hypoxia inducible factor in hepatocellular carcinoma: A therapeutic target
Manuscript Source	Invited Manuscript
All Author List	Daniel Lin and Jennifer Wu
Funding Agency and Grant Number
Corresponding Author	Jennifer Wu, MD, Assistant Professor of Medicine, NYU School of Medicine, Subdivision of GI Oncology, Perlmutter Cancer Center, NYU Langone Medical Center, Division of Hematology and Oncology, 550 First Avenue, BCD 556, New York, NY 10016, United States. jennifer.wu@nyumc.org
Key Words	Hypoxia; Hypoxia-inducible factor alpha; Hepatocellular carcinoma; Vascular endothelial growth factor
Core Tip	Beyond sorafenib, limited systemic treatment options exist for the treatment of advanced hepatocellular carcinoma (HCC). Hypoxia and hypoxia-inducible factor alpha (HIF-1alpha) have emerged as important factors in the development of HCC. This review focuses on the scientific background and pre-clinical data of HIF-1alpha and will conclude in a discussion of the clinical relevance of this transcription factor and its potential therapeutic role, particularly in combination with other therapies, in HCC. A phase IB clinical trial to investigate a HIF-1alpha mRNA antagonist in HCC patients who have failed first line systemic treatment is currently underway.
Publish Date	2015-11-11 13:34
Citation	Lin D, Wu J. Hypoxia inducible factor in hepatocellular carcinoma: A therapeutic target. World J Gastroenterol 2015; 21(42): 12171-12178
URL	http://www.wjgnet.com/1007-9327/full/v21/i42/12171.htm
DOI	http://dx.doi.org/10.3748/wjg.v21.i42.12171

Full Article (PDF)	WJG-21-12171.pdf
Full Article (Word)	WJG-21-12171.doc
Manuscript File	18991-Review.docx
Answering Reviewers	18991-Answering reviewers.pdf
Audio Core Tip	18991-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	18991-Conflict-of-interest statement.pdf
Copyright License Agreement	18991-Copyright assignment.pdf
Peer-review Report	18991-Peer-review(s).pdf
Scientific Misconduct Check	18991-Scientific misconduct check.pdf
Scientific Editor Work List	18991-Scientific editor work list.pdf